Abstract
Dronedarone is a novel multichannel blocker with antiadrenergic and vasodilatory properties. The aim of this study was to investigate the effects of dronedarone on functional capacity in patients with severe left ventricular (LV) dysfunction and compensated stable heart failure (HF). This was a multicentre, double-blind, randomized, placebo-controlled, dose-escalating study. Patients in sinus rhythm with impaired LV function (LV ejection fraction [LVEF] ≤ 30%) and compensated HF (New York Heart Association [NYHA] class I-II), who would continue to receive cardiovascular treatment (excluding antiarrhythmic agents), were eligible. A total of 124 patients were randomized to receive dronedarone (400 mg or 800 mg once daily or 600 mg twice daily) or placebo for 30 days. The primary objective was assessment of the effects of dronedarone on functional capacity, using the 6 min walk test. Secondary objectives included the effects of dronedarone on LVEF, cardiothoracic ratio, NYHA status, and Holter parameters. A total of 111 patients completed the study. There were no significant differences between dronedarone and placebo with respect to walking distance and LVEF. The cardiothoracic ratio was similar in all treatment groups throughout...Continue Reading
References
Aug 1, 1991·Stroke; a Journal of Cerebral Circulation·P A WolfW B Kannel
Mar 8, 1986·British Medical Journal·D P LipkinP A Poole-Wilson
May 1, 1995·The American Journal of Medicine·A D KrahnT E Cuddy
Sep 16, 1998·Circulation·E J BenjaminD Levy
Dec 21, 2000·JAMA : the Journal of the American Medical Association
Oct 29, 2002·The American Journal of Medicine·Simon StewartJohn J V McMurray
Aug 16, 2003·European Heart Journal·Paul TouboulStefan H Hohnloser
Apr 20, 2005·Journal international de bioéthique = International journal of bioethics·UNKNOWN World Medical Association General Assembly
Mar 17, 2006·Drugs of Today·Karolina M Zareba
Sep 22, 2006·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Valentin FusterUNKNOWN Heart Rhythm Society
Jan 25, 2007·Expert Opinion on Investigational Drugs·Kristen K Patton, Richard L Page
Mar 29, 2007·The Annals of Pharmacotherapy·Krista M Dale, C Michael White
Aug 28, 2007·Journal of the American College of Cardiology·Kim FoxUNKNOWN Heart Rate Working Group
Sep 7, 2007·The New England Journal of Medicine·Bramah N SinghUNKNOWN EURIDIS and ADONIS Investigators
Jun 21, 2008·The New England Journal of Medicine·Lars KøberUNKNOWN Dronedarone Study Group
Sep 2, 2008·American Heart Journal·Jean-Marc DavyUNKNOWN ERATO Study Investigators
Feb 14, 2009·The New England Journal of Medicine·Stefan H HohnloserUNKNOWN ATHENA Investigators
May 1, 2009·The New England Journal of Medicine·Peter J Zimetbaum
Nov 6, 2009·Journal of the Indian Medical Association·UNKNOWN World Medical Association Inc
Citations
Nov 16, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN PALLAS Investigators
Mar 20, 2012·Expert Opinion on Pharmacotherapy·Sheila A Doggrell, Jules C Hancox
Dec 20, 2012·The Annals of Pharmacotherapy·James M HollandsAndrew M Kates